J

Johnson & Johnson

Makes prescription drugs and medical devices

Strategy & Execution Co-op - Prostate

Fall 2026Posted on 8/13/2026Deadline 8/26/26
CA$23 - CA$33/hr
Internship
Bachelor's, PharmD
Toronto, ON, Canada
Remote
Medical, Clinical & Veterinary, Clinical Support & Patient Administration

About the job

Requirements
  • Available to work for the duration of the 12-month co-op term.
  • Strong interest in pharmaceutical or biotechnology medical affairs, oncology, prostate cancer, scientific communications, or healthcare strategy.
  • Foundational understanding of clinical research, medical literature, and evidence-based scientific communication.
  • Proficiency with Microsoft Office applications, especially PowerPoint, Word, Excel, and Outlook.
  • Strong written and verbal communication skills.
  • Strong organizational skills, attention to detail, and ability to manage multiple priorities.
  • Ability to work independently and collaboratively in a cross-functional team environment.
  • Authorized to work in Canada on a full-time basis without the need for future sponsorship.
  • Remain actively enrolled in an academic program throughout the entire internship.
  • Available to work 37.5 hours during the entire internship.
  • Record of strong academic performance, with a recommended grade point average of 2.8 or above.
Responsibilities
  • Support execution of apalutamide medical affairs priorities, including prostate cancer scientific strategy, launch readiness, and cross-functional alignment.
  • Track, organize, and follow up on key deliverables across medical affairs workstreams.
  • Synthesize scientific and strategic information into concise summaries, trackers, and project updates for internal stakeholders.
  • Support development of materials that enable consistent scientific communication across internal teams and regional partners.
  • Capture meeting outputs and action items in meeting minutes for post-meeting distribution twice per month.
  • Assist with planning and execution of healthcare professional engagement activities, advisory boards, scientific exchange meetings, and related follow-up materials.
  • Prepare discussion guides, pre-read materials, insight-capture templates, and post-meeting summaries.
  • Organize and synthesize healthcare professional insights to inform medical strategy, content refinement, and future engagement planning.
  • Develop, refine, and format scientific slide decks, internal updates, and presentation materials.
  • Ensure consistency of scientific messaging, references, visual standards, and slide flow across materials.
  • Adapt complex scientific information into clear, concise formats for internal medical affairs audiences.
  • Collaborate with medical, agency, and cross-functional partners to incorporate feedback and maintain version control.
  • Support updates to scientific communication platform materials, including disease-state, product, and evidence-based content.
  • Organize references, review content for consistency, and maintain alignment across related communication resources.
  • Identify opportunities to improve the usability, clarity, and consistency of core scientific materials.
  • Contribute to internal tools and resources that help teams communicate scientific information consistently.
  • Develop and maintain frequently asked questions, objection handlers, and related medical communication resources.
  • Support One J&J voice deliverables by aligning content across internal stakeholders and ensuring consistent terminology, structure, and message flow.
  • Consolidate inputs from medical, regional, and cross-functional partners into clear draft materials for review.
  • Prepare concise response documents and internal summaries addressing anticipated scientific questions.
  • Support planning and execution activities for major oncology and urology congresses.
  • Assist with congress preparation materials, abstract and session tracking, competitive intelligence summaries, medical insights capture, and post-congress reports.
  • Prepare internal pre- and post-congress communication materials, including one-page summaries, slide updates, and key takeaways.
  • Coordinate congress-related deliverables across medical affairs and cross-functional teams.
  • Support social media and digital landscape analysis related to prostate cancer congresses, apalutamide, and relevant scientific topics.
  • Identify, organize, and summarize emerging themes, discussion trends, and scientific conversation topics from approved sources and tools.
  • Maintain scientific objectivity and avoid unsupported interpretation when summarizing external discussions.
  • Maintain project trackers, timelines, action logs, and meeting notes for assigned workstreams.
  • Coordinate with internal stakeholders to gather inputs, track feedback, and support completion of deliverables.
  • Handle scientific and business-sensitive information with professionalism, discretion, and accountability.
Desired Qualifications
  • PhD/PharmD candidate, graduate student, or recent graduate with academic experience in pharmacy, biomedical sciences, pharmacology, epidemiology, public health, medical sciences, or a related field.
  • Prior coursework, research, rotation, internship, or work experience in oncology, urology, medical affairs, clinical development, medical information, regulatory affairs, or medical communications.
  • Experience creating or refining slide decks, scientific summaries, or educational materials.
  • Familiarity with oncology terminology, clinical trial design, and common evidence-generation concepts.
  • Interest in prostate cancer, genitourinary oncology, launch readiness, congress strategy, or scientific communications.
  • Comfort working with digital tools, dashboards, social listening outputs, or structured trackers.

About the company

Johnson & Johnson develops prescription medicines and makes medical devices for hospitals, and unlike most big drugmakers, it runs both businesses under one roof. In 2015, its Darzalex became the first antibody drug approved for multiple myeloma, a blood cancer. Its medicines treat cancer, immune diseases such as psoriasis, and mental illnesses such as depression, and patented drugs bring in most of its sales. Its MedTech unit makes heart pumps, catheters that treat irregular heartbeats, surgical sutures, and Acuvue contact lenses. It was founded in 1886 to make sterile surgical dressings, is based in New Brunswick, New Jersey, and spun off its consumer brands, such as Tylenol and Band-Aid, as Kenvue in 2023.

Company Size

10,001+

Company Stage

IPO

Headquarters

New Brunswick, New Jersey

Founded

1886

Get referred to Johnson & Johnson

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Cancer drugs drive growth: oncology sales rose 17% to $7.4 billion in the June 2026 quarter, 29% of the total.
  • Stock grants have gained value: J&J shares rose 58% in the year to September 2026, versus 23% for Pfizer.
  • Students have a way in: J&J listed 1,897 open jobs in October 2026, including 201 internships, co-ops and early-career roles.

What critics are saying

  • Its key immune drug trails: AbbVie's Skyrizi outsold Tremfya $5.5 billion to $2.0 billion in the June 2026 quarter.
  • Orthopedics is leaving J&J: in September 2026, it was negotiating a $20 billion sale to buyout firm Apollo.
  • Baby powder suits remain costly: in July 2026, J&J agreed to pay $5.5 billion to end about 76,000 cancer claims.

What makes Johnson & Johnson unique

  • Its debt is rated safer than America's: S&P's top AAA rating goes to only two US companies, J&J and Microsoft.
  • Employees rank above shareholders: J&J's 1943 Credo lists duties to patients, then staff and communities, with stockholders last.
  • Its psoriasis pill is a first: Icotyde, approved March 2026, blocks an immune signal rivals target only by injection.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Remote Work Options

Performance Bonus

Growth & Insights and Company News

Headcount

6 month growth

↓ -2%

1 year growth

↓ -2%

2 year growth

↓ -1%
Yahoo Finance
Oct 11th, 2026
J&J reports Q3 results on October 13 as $622.84B giant eyes $2.82 EPS

Johnson & Johnson will report third-quarter results on October 13, before the market opens. Analysts expect earnings per share (EPS) to edge up to $2.82, and the company has beaten EPS estimates in each of the past four quarters. The healthcare group, valued at $622.84 billion, has seen its stock rise 36.8% over 52 weeks. Shares are down 8.1% from their September 2 high of $281.07. In the second quarter, sales rose 6.6% to $25.31 billion, and adjusted EPS climbed 4.7% to $2.90. J&J raised its 2026 adjusted EPS estimate from $11.55 to $11.68. Of 25 analysts, 14 rate the stock "Strong Buy." The consensus price target of $282.60 implies 9.3% upside.

Yahoo Finance
Sep 18th, 2026
J&J stock trades at 28x earnings, but STELARA biosimilar hit distorts valuation

Johnson & Johnson stock has surged 57% over the past year, outpacing the S&P 500's 17% return. Trading at approximately $270 per share, the stock appears expensive at 28.3 times trailing earnings. However, those trailing figures include STELARA, which lost market share to biosimilar competition and reduced operational sales growth by 460 basis points in Q2 2026. Excluding STELARA, the company achieved double-digit growth. The forward outlook looks more attractive, with the stock trading at 24.1 times fiscal 2026 earnings and 20.9 times 2027 estimates. Johnson & Johnson's portfolio includes 28 products generating over $1 billion annually each, with trailing twelve-month revenue near $98 billion. Meanwhile, TREMFYA grew 71% in Q2 2026, becoming the fastest-growing advanced therapy in Crohn's disease and ulcerative colitis. Operating margins improved to 26.8% from a three-year average of 25.7%, supporting expectations for continued margin expansion.

Yahoo Finance
Sep 14th, 2026
Apollo in talks to acquire J&J's orthopedics unit for $20B

Johnson & Johnson shares rose 1.3% in pre-market trading following reports that Apollo Global Management is in discussions to acquire its orthopedics business for approximately $20 billion. Bloomberg News reported the potential deal could be finalised within weeks, citing people familiar with the matter. The orthopedics division generated $9.3 billion in revenue in 2025. However, the business has faced thousands of lawsuits related to its hip replacement devices. No transaction has been confirmed. Investors responded positively to news of the reported discussions and the potential valuation of the orthopedics unit.

Yahoo Finance
Sep 3rd, 2026
J&J rises 1% as AbbVie's myeloma drug shows 74% response rate

Johnson & Johnson shares rose roughly 1% to $277.96 Thursday after AbbVie announced its experimental multiple-myeloma drug, etentamig, achieved a 74% response rate and reduced the risk of disease progression or death by 60% compared to standard therapies. AbbVie's trial positions a convenient monthly treatment in the myeloma market for potential outpatient use. However, J&J is defending its growing franchise, with Carvykti driving 6.8% operational growth in Innovative Medicine during the second quarter. According to Reuters, etentamig appears most differentiated after CAR-T therapy rather than as a direct Carvykti substitute. The market is treating AbbVie's advancement as category expansion rather than a direct threat to J&J. J&J's current share price stands 44.08% above its $192.92 valuation estimate, making future safety and durability data critical for investors.

Yahoo Finance
Sep 1st, 2026
P&G commits $10B in dividends amid 2.8B productivity savings while J&J's 28.5% stock surge masks mid-2027 spinoff risk

Procter & Gamble's dividend strategy is outpacing Johnson & Johnson's despite J&J's stronger stock performance this year. J&J's forward annualised dividend of $5.36 exceeds P&G's $4.354, but its planned mid-2027 DePuy Synthes spinoff threatens its dividend streak. P&G CEO Shailesh Jejurikar committed $10 billion in dividends and $5 billion in buybacks for fiscal 2027, supported by $2.8 billion in productivity savings. The company returned over $15 billion to shareholders in fiscal 2026, including more than $10 billion in dividends. J&J's stock surged 28.5% year-to-date versus P&G's 1.3% gain, driven by strong product performance. However, the upcoming spinoff poses uncertainty, as similar corporate events have disrupted other companies' dividend streaks. P&G faces no such structural risk.

INACTIVE